Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novartis To Add Warning On Blood Pressure Drug Rasilez On CHMP Recommendation

RELATED NEWS
Trade NVS now with 

Novartis AG (NVS: Quote) Friday reported the conclusion of a risk-benefit review of its high blood pressure drug Rasilez by the European Medicines Agency's, or EMA's, Committee for Medicinal Products for Human Use, or CHMP. The Committee recommended that the product information for Rasilez in the EU should warn against use by patients who are also taking an ACE inhibitor or an ARB.

The review, which followed Novartis's decision to terminate its ALTITUDE study in the wake of a high incidence of adverse events, found that patients who have diabetes or mild-to-moderate renal impairment should consult a physician before using a combination product containing aliskiren, for which Rasilez is the trade name. The update also applies to other aliskiren products such as Sprimeo, Riprazo and Rasilamlo.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. has replaced its head of product Daniel Graf just six months after luring him over from Google, according to multiple reports. Graf, previously known for his work leading Google Maps, will retain his vice president of product title and work on Twitter's geolocation features, the Wall... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Visa Inc., the world's largest payment card processor, said Wednesday that its fourth quarter profit fell 10% from last year, hurt mainly by a hefty litigation provision even as revenue increased 9%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.